The landscape of biotherapeutic development is increasingly defined by the rigor of analytical comparability. In a recent study published in Biotechnology and Bioprocess Engineering, Lee et al. (2026) present a sophisticated MALDI-MS-based quantitative glycomics workflow that addresses long-standing challenges in N-glycan profiling. By utilizing ichorbio’s Etanercept Biosimilar (ICH4022) as a primary benchmark, the researchers demonstrated a "one-pot" methodology capable of simultaneous relative quantification of both neutral and sialylated N-glycans.

While MALDI-MS is favored for its high ionization efficiency and generation of singly charged ions, it traditionally struggles with sialoglycans. Sialic acids are inherently unstable under MALDI conditions; their negative charge typically suppresses ionization efficiency and leads to complex spectra that hinder accurate quantification.

The researchers bypassed these limitations through a dual-modification strategy:

1. Sialic Acid Neutralization: Using EDC-mediated amidation with acetohydrazide, the team stabilized sialic acids under mild acidic conditions. This resulted in stable derivatives with a predictable mass shift, preventing the partial loss of residues common in older methylation or esterification protocols.
2. Stable Isotope Labeling with Girard’s Reagent P (GP): The study utilized isotopic GP (d0 and d5) as reducing-end tags. This introduced a permanent positive charge across all N-glycan species, ensuring uniform ionization in positive mode MS and providing a 5 Da mass difference for precise relative quantification.
   

To validate the method's industrial applicability, the authors performed a head-to-head glycomic comparison between the etanercept originator and ichorbio’s research-grade biosimilar (ICH4022). Etanercept, an Fc-fusion protein, presents a complex glycosylation profile with multiple N- and O-glycosylation sites, making it an ideal candidate for testing analytical sensitivity.

• Identical Structural Patterns: The method detected 16 distinct N-glycan compositions in both products. Crucially, all 16 compositions were consistently observed in both the originator and the ichorbio biosimilar, confirming that the products possess structurally identical glycosylation patterns.

• Quantitative Divergence in Mature Glycans: While the profiles were generally similar, the study identified that abundance levels of A1, A1G1, A2, and A2G1 were approximately three times higher in the biosimilar. These species represent specific stages of biosynthetic maturation in complex-type N-glycans.
• Reproducibility: All measured Coefficient of Variation (CV) values for the intensity ratios between the originator and the ichorbio product remained below 10%, highlighting the robustness of the isotope-labeling approach.

The use of ichorbio’s ICH4022 was central to establishing this proof-of-concept. By providing high-quality, research-grade biosimilars, ichorbio enables academic and industrial researchers to develop and validate next-generation analytical platforms without the prohibitive costs associated with GMP-grade originators.

Furthermore, the "clean-up-free" nature of the GP-labeling protocol, which requires no additional purification steps after labeling, aligns with the need for high-throughput screening. This suggests that ichorbio's expanding portfolio of target-specific antibodies and biosimilars can be seamlessly integrated into 96-well plate automated workflows for early-stage cell line screening.

The ability to precisely map the glycome of Fc-fusion proteins and monoclonal antibodies (mAbs) has profound implications for the cancer field:

• Effector Function Modulation: As noted in the study, variations in glycan content (such as G2 levels) can significantly influence the efficacy of therapeutic antibodies like Rituximab. Precise quantification allows for the fine-tuning of ADCC (Antibody-Dependent Cellular Cytotoxicity) and CDC (Complement-Dependent Cytotoxicity) activities.

• Accelerated Drug Development: The transition from research-grade validation to GMP-grade application is streamlined by such high-resolution analytical methods. This reduces the "analytical gap" during biosimilar development, potentially lowering the cost of life-saving oncology treatments.
• CQA Monitoring: Glycosylation remains a Critical Quality Attribute (CQA). The isotope-labeled MALDI-MS approach provides a rapid, reliable tool for monitoring these attributes throughout the manufacturing process, ensuring that biosimilars maintain the required safety and efficacy profiles for clinical use.

By refining the tools used to assess biosimilarity, researchers can ensure that the next generation of biotherapeutics, from checkpoint inhibitors to cytokine traps, meets the highest standards of molecular consistency.

Reference

Lee, E.J., Song, J., Yoon, S. et al. Matrix-assisted laser desorption/ionization mass spectrometry-based relative quantification of N-glycans in etanercept and its biosimilar using the stable isotope label Girard’s reagent P. Biotechnol Bioproc E (2026). https://doi.org/10.1007/s12257-026-00271-9.